Carfilzomib
(kar-FIL-zoh-mib) This page contains brief information about carfilzomib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
| US Brand Name(s): |  | Kyprolis |
| | ||
| | ||
| FDA Approved: | | Yes |
Carfilzomib is approved to treat:
- Multiple myeloma that has gotten worse during or after treatment with bortezomib and immunomodulator therapy.
Carfilzomib is also being studied in the treatment of other types of cancer.
More About CarfilzomibDefinition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Targeted Cancer Therapies - Information about the use of this drug to treat cancer.
Clinical Trials Accepting PatientsFind Clinical Trials for Carfilzomib - Check for trials from NCI's list of cancer clinical trials now accepting patients.
Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
Back to Top
